Effects of adalimumab, etanercept and ustekinumab on the expression of psoriasin (S100A7) in psoriatic skin.

Fabio D'Amico, Chiara Trovato, Evangelia Skarmoutsou, Giulio A Rossi, Mariagrazia Granata, Valentina Longo, Pietro Gangemi, Maurizio Pettinato, Maria Clorinda Mazzarino

Journal: Journal of dermatological science 2016;80(1):38-44

PMID: 26276441

Full Text on Elsevier Science View on PubMed

Abstract

BACKGROUND

Psoriasis is a chronic inflammatory skin disease. It is characterized by immune cell activation and altered epidermal differentiation. S100A7 (psoriasin) is overexpressed in psoriasis, suggesting a determinant role of this protein in inflammation and keratinocyte differentiation.

OBJECTIVE

The purpose of this study was to investigate the expression of S100A7 in the skin from psoriatic patients undergoing biological therapy with adalimumab, etanercept or ustekinumab.

METHODS

S100A7 expression and distribution were analyzed by immunohistochemistry.

RESULTS

S100A7, overexpressed in epidermal keratinocytes of psoriatic lesions, was downregulated, under the biological therapy with adalimumab, etanercept or ustekinumab, only in patients achieving a PASI score<15.

CONCLUSIONS

Dysregulation of S100A7 may represent a non-negligible player in the maintenance of psoriasis and the relative epidermal changes. Blockage of S100A7 may represent an additional therapeutic approach in the treatment of psoriasis.

Address: Department of Biomedical and Biotechnological Sciences, University of Catania, Italy. Electronic address: [email protected].; Department of Biomedical and Biotechnological Sciences, University of Catania, Italy.; Unità Operativa Complessa di Dermatologia, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele, Catania, Italy.; Servizio di Anatomia Patologica, Azienda Ospedaliera Universitaria Policlinico-Vittorio Emanuele, Catania, Italy.

DOI: 10.1016/j.jdermsci.2015.07.009

Link outs

Free resources

Medical:

https://medlineplus.gov/psoriasis.html

Other Literature Sources:

https://www.lens.org/lens/search/patent/list?q=ref...

Research Materials:

https://antibodies.cancer.gov/detail/CPTC-S100A7-1

Subscription / membership required

Full Text Sources:

MeSH Terms: Adalimumab, Adult, Aged, Etanercept, Female, Humans, Immunohistochemistry, Male, Middle Aged, Psoriasis, S100 Calcium Binding Protein A7, S100 Proteins, Skin, Ustekinumab, Young Adult